Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
1.310
-0.030 (-2.24%)
Oct 16, 2026, 4:00 PM EDT - Market closed
Allogene Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 4.64 | - | 0.02 | 0.1 | 0.16 | 114.09 | |
Revenue Growth | - | - | -76.84% | -39.10% | -99.86% | - |
Cost of Revenue | 122.52 | 150.15 | 192.3 | 242.91 | 256.39 | 220.18 |
Gross Profit | -117.88 | -150.15 | -192.28 | -242.82 | -256.23 | -106.09 |
Selling, General & Admin | 62.44 | 56.78 | 65.21 | 71.67 | 79.31 | 74.11 |
Operating Expenses | 62.44 | 56.78 | 65.21 | 71.67 | 79.31 | 74.11 |
Operating Income | -180.32 | -206.93 | -257.48 | -314.49 | -335.54 | -180.19 |
Interest Expense | -1.3 | -1.08 | -0.18 | - | - | - |
Interest & Investment Income | 15.81 | 19.29 | 20.15 | 18.31 | 4.57 | 1.71 |
Earnings From Equity Investments | - | - | -1.69 | -10.67 | -12.88 | -4.09 |
Other Non Operating Income (Expenses) | 0.32 | 0.22 | -0.28 | -0.16 | 3.44 | 0.52 |
EBT Excluding Unusual Items | -165.49 | -188.5 | -239.47 | -307.02 | -340.41 | -182.05 |
Gain (Loss) on Sale of Investments | - | - | -1.96 | -7 | - | - |
Asset Writedown | - | -2.38 | -15.72 | -13.25 | - | - |
Pretax Income | -165.49 | -190.89 | -257.15 | -327.27 | -340.41 | -182.05 |
Income Tax Expense | - | - | 0.44 | - | - | - |
Net Income | -165.49 | -190.89 | -257.59 | -327.27 | -340.41 | -182.05 |
Net Income to Common | -165.49 | -190.89 | -257.59 | -327.27 | -340.41 | -182.05 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 254 | 221 | 195 | 157 | 143 | 136 |
Shares Outstanding (Diluted) | 254 | 221 | 195 | 157 | 143 | 136 |
Shares Change | 19.13% | 13.25% | 24.14% | 9.63% | 5.39% | 12.84% |
EPS (Basic) | -0.65 | -0.87 | -1.32 | -2.09 | -2.38 | -1.34 |
EPS (Diluted) | -0.65 | -0.87 | -1.32 | -2.09 | -2.38 | -1.34 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -102.6 | -149.63 | -200.99 | -239.25 | -225.71 | -206.26 |
Free Cash Flow Per Share | -0.40 | -0.68 | -1.03 | -1.52 | -1.58 | -1.52 |
Gross Margin | - | - | - | - | - | -92.99% |
Operating Margin | -3886.14% | - | -1170372.73% | -331044.21% | -215087.18% | -157.94% |
Profit Margin | -3566.68% | - | -1170863.64% | -344489.47% | -218214.10% | -159.57% |
Free Cash Flow Margin | -2211.16% | - | -913609.09% | -251841.05% | -144685.90% | -180.79% |
EBITDA | -168.65 | -194.57 | -243.84 | -300.29 | -321.24 | -169.74 |
EBITDA Margin | - | - | - | - | - | -148.78% |
D&A For EBITDA | 11.67 | 12.36 | 13.64 | 14.2 | 14.3 | 10.45 |
EBIT | -180.32 | -206.93 | -257.48 | -314.49 | -335.54 | -180.19 |
EBIT Margin | - | - | - | - | - | -157.94% |